COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours

Lung Cancer

Volumn 86, Issue 3, 2014, Pages 311-317

  Schiavon, Marco ^a   Marulli, Giuseppe ^a   Nannini, Nazarena ^a   Pasello, Giulia ^b   Lunardi, Francesca ^a   Balestro, Elisabetta ^a   Perissinotto, Egle ^a   Rebusso, Alessandro ^a   Saetta, Marina ^a   Rea, Federico ^a   Calabrese, Fiorella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Adenocarcinoma; Basophils in blood; COPD; Ki 67 MIB1; KRAS; Morphological pattern

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

AGED; ARTICLE; BASOPHIL; CANCER GROWTH; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SMOKING;

EID: 84964199918     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.004     Document Type: Article

References (29)

1. National Heart, Lung, and Blood Institute, National Institutes of Health NHLBI morbidity and mortality chart book on cardiovascular, lung, and blood disease 2012.
2. Decramer M., Rennard S., Troosters T., Mapel D.W., Giardino N., Mannino D., et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008, 5:235-256.
3. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
4. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009, 101:554-559.
5. Tockman M.S., Anthonisen N.R., Wright E.C., Donithan M.G. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987, 106:512-518.
6. Skillrud D.M., Offord K.P., Miller R.D. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med 1986, 105:503-507.
7. de Torres J.P., Marín J.M., Casanova C., Cote C., Carrizo S., Cordoba-Lanus E., et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med 2011, 184:913-919.
8. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:2445-2454.
9. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990, 323:1228-1233.
10. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993, 328:1433-1437.
11. Malkinson A.M. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 2005, 31:57-82.
12. Wang S.Y., Hu Y.L., Wu Y.L., Li X., Chi G.B., Chen Y., et al. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996, 14:S99-S105.
13. Papi A., Casoni G., Caramori G., Guzzinati I., Boschetto P., Ravenna F., et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004, 59:679-681.
14. Jemal A., Siegel R., Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225.
15. Villa C., Cagle P.T., Johnson M., Patel J.D., Yeldandi A.V., Raj R., et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med 2014, 26.
16. Rekhtman N., Ang D.C., Riely G.J., Ladanyi M., Moreira A.L. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013, 26:1307-1319.
17. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
18. Vallières E., Shepherd F.A., Crowley J. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4:1049-1059.
19. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
20. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
21. Davidson M.R., Gazdar A.F., Clarke B.E. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 2013, 5:S463-S478.
22. Travis W.D., Brambilla E., Riely G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
23. Anthony H.M. Blood basophils in lung cancer. Br J Cancer 1982, 45:209-216.
24. Kolb E., Müller E. Local responses in primary and secondary human lung cancers. II. Clinical correlations. Br J Cancer 1979, 40:410-416.
25. Warth A., Muley T., Meister M., Stenzinger A., Thomas M., Schirmacher P., et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012, 30:1438-1446.
26. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005, 92:131-139.
27. Garassino M.C., Borgonovo K., Rossi A., Mancuso A., Martelli O., Tinazzi A., et al. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009, 29:2691-2697.
28. Bonanno L., Schiavon M., Nardo G., Bertorelle R., Bonaldi L., Galligioni A., et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010, 30:5121-5128.
29. Germain C., Gnjatic S., Tamzalit F., Knockaert S., Remark R., Goc J., et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014, 189:832-844.